CTOs on the Move

ALung Technologies

www.alung.com

 
ALung Technologies has developed the Hemolung Respiratory Assist System (RAS), a dialysis-like alternative or supplement to mechanical ventilation. The Hemolung RAS provides Respiratory Dialysis,a simple, less invasive form of extracorporeal CO2 removal. By removing carbon dioxide and delivering oxygen directly to the blood, the Hemolung RAS allows the patients lungs to rest and heal. Applications of the device include preventing intubation in acute exacerbation of chronic obstructive pulmonary disease (COPD) and enabling ultra-protective ventilation in acute respiratory distress syndrome (ARDS).
  • Number of Employees: 5K-10K
  • Annual Revenue: $1-10 Million
  • www.alung.com
  • 2500 Jane St Ste 1
    Pittsburgh, PA USA 15203
  • Phone: 412.697.3370

Executives

Name Title Contact Details

Funding

ALung Technologies raised $10.53M on 12/04/2015
ALung Technologies raised $36M on 04/12/2017

Similar Companies

U-Metco

U-Metco, Inc. is a Detroit, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Via Biomedical

Via Biomedical is a Osseo, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GlobalMed

GlobalMed Inc. is a Trenton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RenalGuard Solutions

Headquartered in Milford, Massachusetts, RenalGuard Solutions, Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Our newest product, RenalGuard®, has been developed to help prevent the onset of contrast-induced nephropathy (CIN) in at-risk patients undergoing certain imaging procedures. It is already approved for sale in the EU for general fluid balancing. Two investigator-sponsored European studies have demonstrated RenalGuard`s effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by the FDA. The RenalGuard System™ consists of a closed loop, software-controlled console and single-use sets that physicians and nurses use for automated matched fluid replacement to minimize over- or under-hydration of patients during medical procedures where creating and maintaining high urine outputs is beneficial.

Nuwellis

We are Nuwellis, (Nasdaq: NUWE) formerly CHF Solutions. Our solutions go beyond chronic heart failure, so we`ve rebranded to reflect our therapeutic focus areas: heart failure, critical care, and pediatric fluid imbalance. We are a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. Our Aquadex SmartFlow® System gently removes fluid from adult and pediatric patients weighing 20 kg or more. Nuwellis consists of a purpose-driven team that puts patients and their providers at the center of everything we do. This is the new well. And for those whose lives and life`s work are transformed by our fluid management technologies, the new well is everything. Nuwellis is headquartered in Minneapolis, Minn., with a wholly-owned subsidiary in Ireland. The Company has been listed on the Nasdaq Capital Market since February 2012, previously branded as CHF Solutions.